We are leveraging our technological expertise to provide cell engineering tools and services to our customers in three key areas of the therapeutics ecosystem:
The demand for life science tools designed to understand drug-gene interactions and the genetic basis of disease.
Drug discovery and development
The need to improve the efficiency and efficacy of drug development by factoring in genetic components to drug development workflows, allowing better choice of targets through a more accurate choice of clinical trial cohort and improved probability of success of a clinical trial and eventual product approval.
The demand for tools to enable production of new therapeutics or better therapeutic approaches, including precision medicines such as cell and gene therapies, and immuno-oncology.
Our purpose is to continue to be the world’s leader in designing and engineering genetically modified cells for research/clinical applications that advance human health.
We will do this by being a sustainably profitable business that is driven by customer demand for our market-leading products and services.
Expand our tools and services offerings
Develop and commercialise tools and services that address high-growth end markets: Screening, BioProduction and Base Editing
Grow revenues from existing customers and win new customers
Increase penetration within our target customers and secure larger share of their global budget spend
Automate and scale our business
Drive operational leverage in our business through investment in people, processes and automation
Continue to innovate
Extend our capabilities through both internal R&D as well as inlicensing, partnerships, acquisitions and collaborations
People – invest in top talent
Recruit and retain the talented individuals we need to drive our business forward.
A strong and focused leadership team
Board members come from a broad range of backgrounds and have the depth of skills and experience needed to provide effective guidance to the executive leadership of Horizon as they drive the Group into its profitable growth phase.
Built upon decades of experience in the engineering of cell lines, we have created a unique and high value portfolio of tools and services that support and enable critical elements of the drug development and therapeutic value chain. We believe this expertise forms the basis of a sustainable competitive position.
Horizon launches Cas9 and dCas9-VPR stable cell lines
Cambridge, UK, 07 July 2020: Horizon Discovery Group plc today announced the introduction of its…
Cambridge, UK, 07 July 2020: Horizon Discovery Group plc today announced the introduction of its stably expressing Cas9 and dCas9-VPR cell lines to help accelerate gene knockout and gene activation experiments, respectively. The cell lines are optimized to work alongside Horizon’s Edit-R predesigned synthetic single guide RNA (sgRNA) and CRISPRa guide RNA, offering researchers a…Read more
Rentschler Biopharma licenses Horizon’s CHOSOURCETM platform
Cambridge 19 May 2020: Horizon Discovery and Rentschler Biopharma SE, a world-class contract development and…
Cambridge 19 May 2020: Horizon Discovery and Rentschler Biopharma SE, a world-class contract development and manufacturing organization (CDMO) for biopharmaceuticals, have today announced the signing of a commercial license agreement which will see Horizon’s CHOSOURCE™ platform used in combination with Rentschler Biopharma’s novel in-house process for cell line development for difficult-to-express proteinsRead more
Horizon extends OncoSpan reference standards to FFPE & Liquid Biopsy
Cambridge, UK, 29 April 2020: Horizon Discovery Group plc (LSE: HZD) (“Horizon”, “the Company” or…
Cambridge, UK, 29 April 2020: Horizon Discovery Group plc (LSE: HZD) (“Horizon”, “the Company” or “the Group”), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced it has added two new sample formats to its cell-based OncoSpan reference standards for use in the development and validation…Read more